In vitro and In Silico Investigation of Antileishmanial Activity of 1,2,3-Triazole Tethered 2,3-Dihydroquinazolin-4-[1H]-one Conjugates Against L. Infantum
This study reports the synthesis and evaluation of 1,2,3-triazole-tethered 2,3-dihydroquinazolinone conjugates as potential antileishmanial agents against *L. infantum*, identifying compound 6c as the most promising candidate with favorable in vitro activity, predicted binding to pteridine reductase 1, and acceptable ADMET profiles.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Leishmaniasis is a hidden struggle fought within the microscopic world of the human body, caused by a single-celled parasite that hides inside our immune cells. This disease, which can range from disfiguring skin sores to a fatal fever that ravages internal organs, is spread by the bite of a sandfly. While the world has a handful of drugs to treat it, the options are few, often toxic, and sometimes failing as the parasite learns to resist them. The search for a better cure relies on a strategy called molecular hybridization, a method where scientists take two different chemical structures known to have biological power and stitch them together into a single new molecule. The hope is that this new hybrid will inherit the best traits of both parents: the ability to attack the parasite and the safety to spare the human host. In this context, two specific chemical shapes have drawn attention: the triazole ring, a small, stable triangle of atoms found in many medicines, and the dihydroquinazolinone, a larger, fused structure that has shown promise against various diseases.
A team of researchers from India, Italy, Spain, Finland, and Saudi Arabia set out to test whether combining these two shapes could create a powerful weapon against Leishmania infantum, the specific parasite responsible for the most dangerous form of the disease. They designed and built a small library of new chemical compounds, each one a unique variation of the triazole and dihydroquinazolinone hybrid. To see if these new molecules worked, they did not just rely on computer models; they tested them in the real world. First, they exposed the parasites in a dish to the new chemicals and watched to see how many died. Then, they moved to a more complex test, placing the parasites inside mouse cells that mimic the human immune system, to see if the drugs could kill the hidden invaders without harming the cells themselves.
The results revealed a clear winner among the new compounds based on raw laboratory power. One specific molecule, which the researchers labeled 6c, proved to be the most effective in the lab. In the test against the hidden, intracellular form of the parasite, this compound reduced the number of surviving parasites by half at a concentration of just 11.48 micromoles. While this was not as potent as the current standard drug, miltefosine, which worked at a lower concentration of 4.8 micromoles, the new compound showed a crucial advantage: it was safe for the host cells. The researchers calculated a safety score, known as a selectivity index, which compares how toxic a drug is to the host versus how deadly it is to the parasite. Compound 6c achieved a score of 4.88, indicating it could kill the parasite while leaving the healthy cells largely unharmed. Other compounds in the group showed weaker activity, and some failed to work at all, suggesting that the specific arrangement of atoms on the molecule's surface is critical for success.
However, when the scientists looked beyond the lab results to a broader picture using advanced computer analysis, the ranking shifted. They ran a comprehensive check to ensure these new drugs would behave well in the human body, predicting how the compounds would be absorbed, distributed, and broken down, as well as how likely they were to cause toxicity or interact with the wrong human proteins. This systems-level check revealed that while 6c was strong in the lab, two other compounds, 6a and 6b, offered a better overall balance. These two emerged as the most promising candidates because they combined strong antiparasitic activity with even more favorable safety profiles and drug-like properties than 6c. This highlights that the best drug candidate isn't always the one that kills the parasite fastest in a dish, but the one that offers the best combination of killing power and safety for the patient.
To understand why the top compounds worked so well, the scientists looked inside the parasite's machinery. They focused on an enzyme called pteridine reductase 1, a vital tool the parasite uses to survive and multiply. Using powerful computer simulations, they modeled how the new drugs fit into the active site of this enzyme, much like a key fitting into a lock. The simulations showed that the most active compounds settled deeply into the enzyme's pocket, forming a tight network of connections with the surrounding amino acids. They held on with specific chemical bonds and stacking interactions that kept them firmly in place, effectively jamming the enzyme and stopping the parasite from functioning. In contrast, a less effective compound from the same group, labeled 6d, failed to hold its position; it slipped out of the pocket quickly, unable to block the enzyme. This difference in how the molecules behaved inside the computer model perfectly matched their performance in the lab tests.
The study concludes that this specific combination of chemical shapes offers a promising path forward for fighting leishmaniasis. While the work is still in the early stages and requires further testing to confirm its safety and efficacy in humans, the findings provide a strong foundation. The researchers have identified lead compounds that balance the difficult trade-off between killing the parasite and protecting the patient. By combining wet-lab experiments with deep computational analysis, the team has mapped out a clear route for optimizing these molecules, turning a theoretical design into a tangible hope for a new generation of treatments against a neglected tropical disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.